(Boursier.com) — Predilife a specialist in artificial intelligence methods to predict the risks of pathologies for personalized medicine, wishes to complete the press release of January 4 relating to the volume of sales of predictive assessments in 2022…
The contracts signed in 2022 for a total amount of 370 kE break down into:
– 133 kE of predictive tests marketed via doctors and hospitals;
– 237 kE of predictive assessments with companies for their employees
From the first half of 2022, Predilife launched the marketing of predictive assessments to companies for their employees in addition to its distribution channel to doctors and hospitals. This offer intended for companies is part of a general movement to take charge of the health of employees illustrated by the occupational health law which came into force on March 31, 2022 or the “working with cancer” initiative supported by many French companies. and international.
Predilife explains: “All of these orders of 237 kE, which correspond to the volume of sales subject of the press release dated January 4, 2023, were invoiced in 2022. They will be recognized in turnover in proportion to the progress of performance of the services, a part thus being recognized in 2023. The analysis of the advance of services at the end of the 2022 financial year being in progress, the company will then communicate the turnover for fiscal year 2022”.
©2023 Boursier.com